title: [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
abstract: BACKGROUND
  Preclinical studies have shown that irinotecan (CPT-11) and cisplatin (CDDP) can act synergistically. Several chemotherapy regimens combining CPT-11 and CDDP for advanced gastric cancer have been reported to demonstrate high response rates and high incidence of severe toxicity.
  
  
  OBJECTIVE
  We conducted a combination chemotherapy regimen of low-dose CDDP and CPT-11 to prolong the time to progression with less toxicity.
  
  
  METHODS
  Seven patients with histologically-confirmed intestinal type of gastric adenocarcinoma were enrolled in this study. All patients were male, and their age at diagnosis ranged from 52 to 76 with a mean age of 64.8. Six patients received combination chemotherapy with CPT-11 and CDDP after the gastrectomy (stage I b: 1, II : 3, III b: 1, IV: 1). Only chemotherapy was administered in one patient because of a far advanced primary lesion and metastatic tumors. Low-dose CDDP (20 mg/body) and CPT-11 (65 mg/m(2)) were administered intravenously once every two weeks.
  
  
  RESULTS
  The overall response rate was 43% including 1 complete response and 2 partial responses. One patient had grade 3 myelosuppression. Other adverse reactions were mild.
  
  
  CONCLUSIONS
  The combination of low-dose CDDP and CPT-11 has mild therapeutic toxicities and may achieve a prolonged median survival time in patients with intestinal- type gastric adenocarcinoma.
authors.affiliation: Dept. of Surgery, Yokohama City Red Cross Hospital.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nagahori
authors.forename: Kaoru
authors.initials: K
authors.lastname: Nagahori
authors.forename: Yohei
authors.initials: Y
authors.lastname: Hamaguchi
authors.forename: Tadao
authors.initials: T
authors.lastname: Fukushima
authors.forename: Hidenobu
authors.initials: H
authors.lastname: Masui
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Mogaki
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Abe
mesh_terms: D000230:Adenocarcinoma / Q000145:classification / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D005773:Gastroscopy; D006801:Humans; D007414:Intestinal Neoplasms / Q000145:classification / Q000473:pathology; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000145:classification / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin